Literature DB >> 8148445

Decreased natural killer cell activity is associated with severity of chronic fatigue immune dysfunction syndrome.

E A Ojo-Amaize1, E J Conley, J B Peter.   

Abstract

Natural killer (NK) cell activity was measured blindly in vitro with blood specimens from 50 healthy individuals and 20 patients with clinically defined chronic fatigue immune dysfunction syndrome (CFIDS) who met the criteria established by the Centers for Disease Control and Prevention (Atlanta). In accordance with a group scoring system of 1-10 points, with 10 being the most severe clinical status, the patient population was stratified into three clinical groups: A (> 7 points), B (5-7 points), and C (< 5 points). NK cell activity was assessed by the number of lytic units (LU), which for the 50 healthy controls varied between 20 and 250 (50%, 20-50 LU; 32%, 51-100 LU; 6%, 101-130 LU; and 12%, > 150 LU). In none of the 20 patients with CFIDS was the NK cell activity > 100 LU. For group C, the 10 patients stratified as having the least severe clinical condition, the measure was 61.0 +/- 21.7 LU; for group B (more severe, n = 7), it was 18.3 +/- 7.3 LU; and for group A (most severe, n = 3), it was 8.0 +/- 5.3 LU. These data suggest a correlation between low levels of NK cell activity and severity of CFIDS, which, if it is confirmed by additional studies of larger groups, might be useful for subgrouping patients and monitoring therapy and/or the progression of CFIDS.

Entities:  

Mesh:

Year:  1994        PMID: 8148445     DOI: 10.1093/clinids/18.supplement_1.s157

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  17 in total

Review 1.  Evidence for the presence of immune dysfunction in chronic fatigue syndrome.

Authors:  Benjamin H Natelson; Mohammad H Haghighi; Nicholas M Ponzio
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

2.  The in vitro immunomodulatory effects of glyconutrients on peripheral blood mononuclear cells of patients with chronic fatigue syndrome.

Authors:  D M See; P Cimoch; S Chou; J Chang; J Tilles
Journal:  Integr Physiol Behav Sci       Date:  1998 Jul-Sep

3.  Natural killer cells in patients with severe chronic fatigue syndrome.

Authors:  E W Brenu; S L Hardcastle; G M Atkinson; M L van Driel; S Kreijkamp-Kaspers; K J Ashton; D R Staines; S M Marshall-Gradisnik
Journal:  Auto Immun Highlights       Date:  2013-04-16

4.  Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME).

Authors:  Sharni Lee Hardcastle; Ekua Weba Brenu; Samantha Johnston; Thao Nguyen; Teilah Huth; Naomi Wong; Sandra Ramos; Donald Staines; Sonya Marshall-Gradisnik
Journal:  BMC Immunol       Date:  2015-06-02       Impact factor: 3.615

5.  Daily intake of probiotics with high IFN-γ/IL-10 ratio increases the cytotoxicity of human natural killer cells: a personalized probiotic approach.

Authors:  Yu-Hsuan Ho; Yu-Chiu Lu; Hung-Cheng Chang; Shin-Yi Lee; Min-Fen Tsai; Yu-Ting Huang; Ting-Yuan Hsu
Journal:  J Immunol Res       Date:  2014-12-11       Impact factor: 4.818

6.  Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.

Authors:  T Nguyen; D Staines; B Nilius; P Smith; S Marshall-Gradisnik
Journal:  Biol Res       Date:  2016-05-31       Impact factor: 5.612

7.  Immune and hemorheological changes in chronic fatigue syndrome.

Authors:  Ekua W Brenu; Donald R Staines; Oguz K Baskurt; Kevin J Ashton; Sandra B Ramos; Rhys M Christy; Sonya M Marshall-Gradisnik
Journal:  J Transl Med       Date:  2010-01-11       Impact factor: 5.531

8.  Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis.

Authors:  Ekua W Brenu; Mieke L van Driel; Donald R Staines; Kevin J Ashton; Sharni L Hardcastle; James Keane; Lotti Tajouri; Daniel Peterson; Sandra B Ramos; Sonya M Marshall-Gradisnik
Journal:  J Transl Med       Date:  2012-05-09       Impact factor: 5.531

9.  Killer Cell Immunoglobulin-like Receptor Genotype and Haplotype Investigation of Natural Killer Cells from an Australian Population of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients.

Authors:  T K Huth; E W Brenu; D R Staines; S M Marshall-Gradisnik
Journal:  Gene Regul Syst Bio       Date:  2016-06-19

10.  ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.

Authors:  Teilah Kathryn Huth; Donald Staines; Sonya Marshall-Gradisnik
Journal:  J Transl Med       Date:  2016-04-21       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.